Objectives: A synthetic mustard, palifosfamide-tris may overcome the tumor resistance seen with ifosfamide. Investigators will compare progression-free survival followed by overall survival when this investigative agent is added to standard therapy with doxorubicin.
Key entry or exclusion criteria: Patients must have untreated metastatic disease. They may not have specific sarcoma histological subtypes including GIST and Ewing’s sarcoma, or any other prior or current systemic therapy for metastatic sarcoma.
Locations: 164 sites.
Goal: 424 patients.
Study sponsor: Ziopharm Oncology Inc.
Links for more information: clinicaltrials.gov/ct2/show/NCT01168791
NIH clinical trials identifier: NCT01168791